Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Everpure, Inc.PSTG · Entity 3140 | 10% owner | January 31, 2018 | February 23, 2018 |
| Mattersight CorpMATR · Entity 164107 | 10% owner | May 31, 2017 | June 02, 2017 |
| Molecular Templates, Inc.THLD · Entity 85987 | Director | May 31, 2017 | June 02, 2017 |
| PORTOLA PHARMACEUTICALS INCPTLA · Entity 147987 | Director | July 02, 2020 | July 07, 2020 |
| Venus Concept Inc.HAIR · Entity 55304 | Director | June 13, 2018 | June 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Everpure, Inc.
Report date January 31, 2018 · Filed February 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | IndirectBy Ltd Partnership (NEST) | 499,478 |
Reported balance
After 2018-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-01 · Gift · Disposed 0 · Balance 499,478 F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025. F2: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein. F3: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 227,244 |
Reported balance
Holding disclosure · report date 2018-01-31 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 227,244 F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectBy Irrevocable Trust (BICT) | 85,404 |
Reported balance
Holding disclosure · report date 2018-01-31 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 85,404 F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025. F4: Shares held by an irrevocable trust for the benefit of the reporting person's children, of which the reporting person is a trustee. The reporting person disclaims any beneficial ownership in these shares. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectBy Ltd Liability Company (SHA) | 1,024,538 |
Reported balance
Holding disclosure · report date 2018-01-31 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 1,024,538 F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025. F5: Shares held by Sutter Hill Associates, LLC ("SHA"). Sutter Hill Ventures, a California Limited Partnership ("SHV") has voting and dispositive power over the shares held by SHA, and the reporting person is a trustee of a trust which is a member of SHA. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectBy Ltd Liability Company (SHM) | 77,100 |
Reported balance
Holding disclosure · report date 2018-01-31 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 77,100 F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025. F6: Shares held by Sutter Hill Management Company, L.L.C ("SHM"). SHV has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectBy Ltd Partnership (SHV As Nominee) | 318,750 |
Reported balance
Holding disclosure · report date 2018-01-31 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 318,750 F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025. F7: Shares held by SHV as a nominee on behalf of, and for the exclusive benefit of a trust (of which the reporting person is a trustee), which is a member of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectBy Ltd Partnership (SHV) | 17,102,128 |
Reported balance
Holding disclosure · report date 2018-01-31 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 17,102,128 F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025. F8: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectBy Trust (Trustees) | 1,281,244 |
Reported balance
Holding disclosure · report date 2018-01-31 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 1,281,244 F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025. F9: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock is convertible at any time at the option of the reporting person into one share of Class A Common Stock and has no expiration date. The Class B Common Stock will convert automatically into Class A Common Stock on the same basis upon the earlier of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's restated certificate of incorporation in effect as of the date hereof, (ii) the affirmative vote of the holders of Class B Common Stock representing not less than a majority of the outstanding shares of Class B Common Stock, or (iii) October 6, 2025.
F2: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein.
F3: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F4: Shares held by an irrevocable trust for the benefit of the reporting person's children, of which the reporting person is a trustee. The reporting person disclaims any beneficial ownership in these shares.
F5: Shares held by Sutter Hill Associates, LLC ("SHA"). Sutter Hill Ventures, a California Limited Partnership ("SHV") has voting and dispositive power over the shares held by SHA, and the reporting person is a trustee of a trust which is a member of SHA. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F6: Shares held by Sutter Hill Management Company, L.L.C ("SHM"). SHV has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F7: Shares held by SHV as a nominee on behalf of, and for the exclusive benefit of a trust (of which the reporting person is a trustee), which is a member of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F8: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F9: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
Mattersight Corp
Report date May 31, 2017 · Filed June 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Ltd Partnership (NEST) | 108,557 |
Reported balance
After 2017-06-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-06-01 · Purchase · Acquired 16,189 · Balance 108,557 F1: In connection with the Liquidation, the reporting person entered into an agreement with the Limited Partner to repurchase 16,189 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017. F2: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the General Partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Ltd Partnership (SHV) | 1,056,194 |
Last balance in matching sequence
After 2017-06-01 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2017-05-31 · Other · Disposed 271,391 · Balance 852,651 F3: On May 31, 2017, a limited partner (the "Limited Partner") of Sutter Hill Ventures, a California Limited Partnership ("SHV") liquidated its interest in SHV in return for its ratable share of the holdings of SHV, resulting in SHV's disposition to the Limited Partner of 271,391 shares (the "Distributed Common Shares") of the Issuer's common stock (the "Liquidation"). F4: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Row 3 · 2017-06-01 · Purchase · Acquired 203,543 · Balance 1,056,194 F5: In connection with the Liquidation, SHV entered into an agreement with the Limited Partner to repurchase 203,543 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017. F4: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust (Trustees) | 71,840 |
Reported balance
Holding disclosure · report date 2017-05-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 71,840 F6: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the Liquidation, the reporting person entered into an agreement with the Limited Partner to repurchase 16,189 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.
F2: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the General Partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F3: On May 31, 2017, a limited partner (the "Limited Partner") of Sutter Hill Ventures, a California Limited Partnership ("SHV") liquidated its interest in SHV in return for its ratable share of the holdings of SHV, resulting in SHV's disposition to the Limited Partner of 271,391 shares (the "Distributed Common Shares") of the Issuer's common stock (the "Liquidation").
F4: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F5: In connection with the Liquidation, SHV entered into an agreement with the Limited Partner to repurchase 203,543 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.
F6: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.
Molecular Templates, Inc.
Report date May 31, 2017 · Filed June 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Ltd Partnership (SHV) | 3,940,573 |
Last balance in matching sequence
After 2017-06-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-05-31 · Other · Disposed 630,770 · Balance 3,467,496 F1: On May 31, 2017, a limited partner (the "Limited Partner") of Sutter Hill Ventures, a California Limited Partnership ("SHV") liquidated its interest in SHV in return for its ratable share of the holdings of SHV, resulting in SHV's disposition to the Limited Partner of 630,770 shares (the "Distributed Common Shares") of the Issuer's common stock (the "Liquidation"). F2: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Row 2 · 2017-06-01 · Purchase · Acquired 473,077 · Balance 3,940,573 F3: In connection with the Liquidation, SHV entered into an agreement with the Limited Partner to repurchase 473,077 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017. F2: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 377,782 |
Reported balance
After 2017-06-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-06-01 · Purchase · Acquired 37,626 · Balance 377,782 F4: In connection with the Liquidation, the reporting person entered into an agreement with the Limited Partner to repurchase 37,626 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017. F5: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 919 |
Reported balance
Holding disclosure · report date 2017-05-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 919 |
Filing footnotes · ownership attribution and instrument terms
F1: On May 31, 2017, a limited partner (the "Limited Partner") of Sutter Hill Ventures, a California Limited Partnership ("SHV") liquidated its interest in SHV in return for its ratable share of the holdings of SHV, resulting in SHV's disposition to the Limited Partner of 630,770 shares (the "Distributed Common Shares") of the Issuer's common stock (the "Liquidation").
F2: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F3: In connection with the Liquidation, SHV entered into an agreement with the Limited Partner to repurchase 473,077 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.
F4: In connection with the Liquidation, the reporting person entered into an agreement with the Limited Partner to repurchase 37,626 Distributed Common Shares from the Limited Partner at a purchase price equal to the average of the mean between the closing bid and ask prices over the ninety (90)-day period ended March 31, 2017.
F5: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
PORTOLA PHARMACEUTICALS INC
Report date July 02, 2020 · Filed July 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-07-02 · Disposition to issuer · Disposed 20,475 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. |
| Common StockSEC Table I · non-derivative | IndirectBy Ltd Liability Company (SHM) | 0 |
Reported balance
After 2020-07-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-07-02 · Disposition to issuer · Disposed 10,007 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. F3: Shares held by Sutter Hill Management Company, L.L.C. ("SHM"). Sutter Hill Ventures, a California Limited Partnership ("SHV") has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Ltd Partnership (NEST) | 0 |
Reported balance
After 2020-07-02 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-07-02 · Disposition to issuer · Disposed 45,402 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. F4: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership of these shares except as to the reporting person's pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust (Trustees) | 0 |
Reported balance
After 2020-07-02 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2020-07-02 · Disposition to issuer · Disposed 458,569 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. F5: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.19 · Expires 2026-06-01 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-07-02 · Disposition to issuer · Disposed 6,000 · Balance 0 F6: In connection with the Merger, these options were canceled without payment. F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.74 · Expires 2023-06-04 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-07-02 · Disposition to issuer · Disposed 14,101 · Balance 0 F6: In connection with the Merger, these options were canceled without payment. F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.81 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-07-02 · Disposition to issuer · Disposed 6,000 · Balance 0 F6: In connection with the Merger, these options were canceled without payment. F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2029-06-12 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-07-02 · Disposition to issuer · Disposed 6,991 · Balance 0 F6: In connection with the Merger, these options were canceled without payment. F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2030-06-12 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0 F7: At the Effective Time, this unvested and outstanding option was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.39 · Expires 2025-06-16 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-07-02 · Disposition to issuer · Disposed 10,000 · Balance 0 F6: In connection with the Merger, these options were canceled without payment. F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.06 · Expires 2027-06-16 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-07-02 · Disposition to issuer · Disposed 6,000 · Balance 0 F6: In connection with the Merger, these options were canceled without payment. F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.19 · Expires 2024-06-27 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-07-02 · Disposition to issuer · Disposed 10,000 · Balance 0 F6: In connection with the Merger, these options were canceled without payment. F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
F2: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.
F3: Shares held by Sutter Hill Management Company, L.L.C. ("SHM"). Sutter Hill Ventures, a California Limited Partnership ("SHV") has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F4: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership of these shares except as to the reporting person's pecuniary interest therein.
F5: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.
F6: In connection with the Merger, these options were canceled without payment.
F7: At the Effective Time, this unvested and outstanding option was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Venus Concept Inc.
Report date June 13, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.89 · Expires 2028-06-13 | Direct | 13,708 |
Reported balance
After 2018-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-13 · Grant · Acquired 13,708 · Balance 13,708 F1: The option will vest in full on the earlier of (A) June 13, 2019 or (B) immediately prior to the next annual meeting of the Company's stockholders, subject to continued service on the board of directors through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in full on the earlier of (A) June 13, 2019 or (B) immediately prior to the next annual meeting of the Company's stockholders, subject to continued service on the board of directors through each applicable vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Forty Seven, Inc.
Report date April 07, 2020 · Filed April 07, 2020
Section 16 reporting ended · disclosed 2020-04-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Ltd Partnership (BBV) | 0 |
Reported balance
After 2020-04-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-04-07 · Disposition to issuer · Disposed 562,500 · Balance 0 F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F2: Shares held by Bluebird Ventures I, L.P. of which the Reporting Person is the managing director of the general partner. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2020-04-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-04-07 · Disposition to issuer · Disposed 233,564 · Balance 0 F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F3: Shares held by the Jeffrey W. and Christina R. Bird Trust of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Ltd Partnership (NEST) | 0 |
Reported balance
After 2020-04-07 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-04-07 · Disposition to issuer · Disposed 215,375 · Balance 0 F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F4: Shares held by NestEgg Holdings, LP of which the Reporting Person is a trustee of a trust which is the general partner. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy LLC (SHM) | 0 |
Reported balance
After 2020-04-07 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2020-04-07 · Disposition to issuer · Disposed 6,596 · Balance 0 F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F5: Shares held by SHM Investments, LLC, a limited liability company of which the Reporting Person is a member. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 · Expires 2028-04-26 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-04-07 · Disposition to issuer · Disposed 20,645 · Balance 0 F6: This option, which provided for vesting over a three-year period as follows: 1/36th of the shares subject to the option vest in a series of 36 successive equal monthly installments beginning on the date of the closing of the Issuer's initial public offering, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $1,790,798.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2029-06-11 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-04-07 · Disposition to issuer · Disposed 10,322 · Balance 0 F7: This option, which provided for vesting on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date, was canceled in the Merger in exchange for a cash payment of $874,170.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.
F2: Shares held by Bluebird Ventures I, L.P. of which the Reporting Person is the managing director of the general partner. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.
F3: Shares held by the Jeffrey W. and Christina R. Bird Trust of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.
F4: Shares held by NestEgg Holdings, LP of which the Reporting Person is a trustee of a trust which is the general partner. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.
F5: Shares held by SHM Investments, LLC, a limited liability company of which the Reporting Person is a member. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein.
F6: This option, which provided for vesting over a three-year period as follows: 1/36th of the shares subject to the option vest in a series of 36 successive equal monthly installments beginning on the date of the closing of the Issuer's initial public offering, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $1,790,798.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
F7: This option, which provided for vesting on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date, was canceled in the Merger in exchange for a cash payment of $874,170.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
Yext, Inc.
Report date December 01, 2017 · Filed December 05, 2017
Section 16 reporting ended · disclosed 2017-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Ltd Liability Company (SHM) | 78,140 |
Reported balance
After 2017-12-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-12-01 · Other · Acquired 78,140 · Balance 78,140 F1: Represents the receipt of shares in the pro rata distribution described below, for no additional consideration, by Sutter Hill Management Company, L.L.C. ("SHM"), a limited partner of Sutter Hill Ventures, a California Limited Partnership ("SHV"). F2: Shares held by SHM. SHV has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Ltd Partnership (SHV As Nominee) | 323,049 |
Reported balance
After 2017-12-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-12-01 · Other · Acquired 323,049 · Balance 323,049 F3: Represents the retention of shares by SHV, in connection with the distribution described below, for the benefit of a trust (of which the reporting person is a trustee), which is a member of the general partner of SHV. F4: Shares held by SHV as a nominee on behalf of, and for the exclusive benefit of a trust (of which the reporting person is a trustee), which is a member of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Ltd Partnership (SHV) | 0 |
Reported balance
After 2017-12-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-12-01 · Other · Disposed 8,614,633 · Balance 0 F5: Effective December 1, 2017, SHV effected a pro rata distribution of 8,614,633 shares of Common Stock to its limited partners and its general partner for no additional consideration, of which 6,460,975 shares were distributed to the limited partners and 2,153,658 shares, representing the general partner's interest in the distribution, were retained by SHV and are now being held by SHV as a nominee on behalf of, and for the exclusive benefit of, the members of the general partner. SHV has no pecuniary interest in such retained shares. F6: Excludes shares of Common Stock held by SHV as a nominee on behalf of, and for the exclusive benefit of, the members of the general partner of SHV. F7: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Irrevocable Trust (BICT) | 35,602 |
Reported balance
Holding disclosure · report date 2017-12-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 35,602 F8: Shares held by an irrevocable trust for the benefit of the reporting person's children of which the reporting person is a trustee. The reporting person disclaims any beneficial ownership in these shares. |
| Common StockSEC Table I · non-derivative | IndirectBy Ltd Partnership (NEST) | 377,280 |
Reported balance
Holding disclosure · report date 2017-12-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 377,280 F9: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 311,959 |
Reported balance
Holding disclosure · report date 2017-12-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 311,959 F10: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the receipt of shares in the pro rata distribution described below, for no additional consideration, by Sutter Hill Management Company, L.L.C. ("SHM"), a limited partner of Sutter Hill Ventures, a California Limited Partnership ("SHV").
F2: Shares held by SHM. SHV has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F3: Represents the retention of shares by SHV, in connection with the distribution described below, for the benefit of a trust (of which the reporting person is a trustee), which is a member of the general partner of SHV.
F4: Shares held by SHV as a nominee on behalf of, and for the exclusive benefit of a trust (of which the reporting person is a trustee), which is a member of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F5: Effective December 1, 2017, SHV effected a pro rata distribution of 8,614,633 shares of Common Stock to its limited partners and its general partner for no additional consideration, of which 6,460,975 shares were distributed to the limited partners and 2,153,658 shares, representing the general partner's interest in the distribution, were retained by SHV and are now being held by SHV as a nominee on behalf of, and for the exclusive benefit of, the members of the general partner. SHV has no pecuniary interest in such retained shares.
F6: Excludes shares of Common Stock held by SHV as a nominee on behalf of, and for the exclusive benefit of, the members of the general partner of SHV.
F7: Shares held by SHV. The reporting person is a managing director and member of the management committee of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F8: Shares held by an irrevocable trust for the benefit of the reporting person's children of which the reporting person is a trustee. The reporting person disclaims any beneficial ownership in these shares.
F9: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
F10: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2020 Filed Jul 7, 2020 15:39 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $29.19 | Not disclosed |
DisclosureSEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 12 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-06-27 F6 · price: In connection with the Merger, these options were canceled without payment. F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 15:39 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $35.06 | Not disclosed |
DisclosureSEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 11 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2027-06-16 F6 · price: In connection with the Merger, these options were canceled without payment. F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 15:39 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $44.39 | Not disclosed |
DisclosureSEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 10 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-16 F6 · price: In connection with the Merger, these options were canceled without payment. F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 15:39 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,377 | Not disclosed Strike: $17.94 | Not disclosed |
DisclosureSEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 9 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,377 shares Expires 2030-06-12 F7 · price: At the Effective Time, this unvested and outstanding option was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F7 · derivative.exercise_date: At the Effective Time, this unvested and outstanding option was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 15:39 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,991 | Not disclosed Strike: $26.09 | Not disclosed |
DisclosureSEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 8 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,991 shares Expires 2029-06-12 F6 · price: In connection with the Merger, these options were canceled without payment. F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 15:39 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $42.81 | Not disclosed |
DisclosureSEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 7 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2028-06-07 F6 · price: In connection with the Merger, these options were canceled without payment. F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 15:39 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,101 | Not disclosed Strike: $19.74 | Not disclosed |
DisclosureSEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 6 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,101 shares Expires 2023-06-04 F6 · price: In connection with the Merger, these options were canceled without payment. F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 15:39 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $24.19 | Not disclosed |
DisclosureSEC source: 0001225208-20-009616 · doc4.xml · derivative · entry 5 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2026-06-01 F6 · price: In connection with the Merger, these options were canceled without payment. F6 · derivative.exercise_date: In connection with the Merger, these options were canceled without payment. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 15:39 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerCommon Stock | 458,569 | $18.00 | $8,254,242.00 |
DisclosureSEC source: 0001225208-20-009616 · doc4.xml · nonDerivative · entry 4 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust (Trustees) Disclosed balance after: 0 F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. F5 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 15:39 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerCommon Stock | 45,402 | $18.00 | $817,236.00 |
DisclosureSEC source: 0001225208-20-009616 · doc4.xml · nonDerivative · entry 3 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (NEST) Disclosed balance after: 0 F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. F4 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership of these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 15:39 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerCommon Stock | 10,007 | $18.00 | $180,126.00 |
DisclosureSEC source: 0001225208-20-009616 · doc4.xml · nonDerivative · entry 2 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Liability Company (SHM) Disclosed balance after: 0 F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. F3 · ownership.nature: Shares held by Sutter Hill Management Company, L.L.C. ("SHM"). Sutter Hill Ventures, a California Limited Partnership ("SHV") has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 15:39 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerCommon Stock | 20,475 | $18.00 | $368,550.00 |
DisclosureSEC source: 0001225208-20-009616 · doc4.xml · nonDerivative · entry 1 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 17:01 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 11,377 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001225208-20-009041 · doc4.xml · derivative · entry 5 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,377 Underlying: Common Stock · 11,377 shares Expires 2030-06-12 F6 · derivative.exercise_date: The option shares shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 17:01 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 7,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-009041 · doc4.xml · nonDerivative · entry 1 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,475 F1 · price: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs will vest fully on March 1, 2021, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other parties pursuant to contractual relationships. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 13:25 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerStock Option (right to buy) · Derivative | 10,322 | Not disclosed Strike: $10.81 | Not disclosed |
DisclosureSEC source: 0001209191-20-023727 · doc4.xml · derivative · entry 6 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,322 shares Expires 2029-06-11 F7 · price: This option, which provided for vesting on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date, was canceled in the Merger in exchange for a cash payment of $874,170.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F7 · derivative.exercise_date: This option, which provided for vesting on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date, was canceled in the Merger in exchange for a cash payment of $874,170.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 13:25 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerStock Option (right to buy) · Derivative | 20,645 | Not disclosed Strike: $8.76 | Not disclosed |
DisclosureSEC source: 0001209191-20-023727 · doc4.xml · derivative · entry 5 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,645 shares Expires 2028-04-26 F6 · price: This option, which provided for vesting over a three-year period as follows: 1/36th of the shares subject to the option vest in a series of 36 successive equal monthly installments beginning on the date of the closing of the Issuer's initial public offering, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $1,790,798.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. F6 · derivative.exercise_date: This option, which provided for vesting over a three-year period as follows: 1/36th of the shares subject to the option vest in a series of 36 successive equal monthly installments beginning on the date of the closing of the Issuer's initial public offering, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $1,790,798.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 13:25 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerCommon Stock | 6,596 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023727 · doc4.xml · nonDerivative · entry 4 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC (SHM) Disclosed balance after: 0 F1 · shares: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F1 · price: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F5 · ownership.nature: Shares held by SHM Investments, LLC, a limited liability company of which the Reporting Person is a member. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 13:25 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerCommon Stock | 215,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023727 · doc4.xml · nonDerivative · entry 3 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (NEST) Disclosed balance after: 0 F1 · shares: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F1 · price: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F4 · ownership.nature: Shares held by NestEgg Holdings, LP of which the Reporting Person is a trustee of a trust which is the general partner. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 13:25 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerCommon Stock | 233,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023727 · doc4.xml · nonDerivative · entry 2 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · shares: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F1 · price: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F3 · ownership.nature: Shares held by the Jeffrey W. and Christina R. Bird Trust of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. Read SEC document |
| April 07, 2020 Filed Apr 7, 2020 13:25 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Disposition to issuerCommon Stock | 562,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023727 · doc4.xml · nonDerivative · entry 1 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (BBV) Disclosed balance after: 0 F1 · shares: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F1 · price: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. F2 · ownership.nature: Shares held by Bluebird Ventures I, L.P. of which the Reporting Person is the managing director of the general partner. The Reporting Person disclaims beneficial ownership in these shares except as to the Reporting Person's pecuniary interest therein. Read SEC document |
| September 03, 2019 Filed Sep 3, 2019 18:04 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | OtherCommon Stock | 9,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-012058 · doc4.xml · nonDerivative · entry 3 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust (Trustees) Disclosed balance after: 458,569 F5 · kind: Represents the receipt of shares in a pro rata distribution effective September 3, 2019, for no additional consideration, from SHV. F5 · shares: Represents the receipt of shares in a pro rata distribution effective September 3, 2019, for no additional consideration, from SHV. F5 · price: Represents the receipt of shares in a pro rata distribution effective September 3, 2019, for no additional consideration, from SHV. F6 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust. Read SEC document |
| September 03, 2019 Filed Sep 3, 2019 18:04 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | OtherCommon Stock | 921,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-012058 · doc4.xml · nonDerivative · entry 2 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (SHV) Disclosed balance after: 0 F3 · kind: Effective September 3, 2019, SHV effected a pro rata distribution to its limited partners and its general partner for no additional consideration. F3 · shares: Effective September 3, 2019, SHV effected a pro rata distribution to its limited partners and its general partner for no additional consideration. F3 · price: Effective September 3, 2019, SHV effected a pro rata distribution to its limited partners and its general partner for no additional consideration. F4 · ownership.nature: Shares held by SHV. The reporting person is a managing director of the general partner of SHV. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| September 03, 2019 Filed Sep 3, 2019 18:04 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | OtherCommon Stock | 10,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-012058 · doc4.xml · nonDerivative · entry 1 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Liability Company (SHM) Disclosed balance after: 10,007 F1 · kind: Represents the receipt of shares in the pro rata distribution described below, for no additional consideration, by Sutter Hill Management Company, L.L.C. ("SHM"), a limited partner of Sutter Hill Ventures, a California Limited Partnership ("SHV"). F1 · shares: Represents the receipt of shares in the pro rata distribution described below, for no additional consideration, by Sutter Hill Management Company, L.L.C. ("SHM"), a limited partner of Sutter Hill Ventures, a California Limited Partnership ("SHV"). F1 · price: Represents the receipt of shares in the pro rata distribution described below, for no additional consideration, by Sutter Hill Management Company, L.L.C. ("SHM"), a limited partner of Sutter Hill Ventures, a California Limited Partnership ("SHV"). F2 · ownership.nature: Shares held by SHM. SHV has voting and dispositive power over the shares held by SHM, and the reporting person is a trustee of a trust which is a member of SHM. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 16:06 UTC | Forty Seven, Inc. FTSV · Entity 16035 | PurchaseCommon Stock | 187,500 | $8.00 | $1,500,000.00 |
DisclosureSEC source: 0001225208-19-010430 · doc4.xml · nonDerivative · entry 2 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 192,419 F2 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 22, 2019 Filed Jul 24, 2019 16:06 UTC | Forty Seven, Inc. FTSV · Entity 16035 | PurchaseCommon Stock | 562,500 | $8.00 | $4,500,000.00 |
DisclosureSEC source: 0001225208-19-010430 · doc4.xml · nonDerivative · entry 1 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (BBV) Disclosed balance after: 562,500 F1 · ownership.nature: Shares held by Bluebird Ventures I, L.P. of which the reporting person is the managing director of the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:06 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 6,991 | $0.00 Strike: $26.09 | $0.00 |
DisclosureSEC source: 0001225208-19-009340 · doc4.xml · derivative · entry 5 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,991 Underlying: Common Stock · 6,991 shares Expires 2029-06-12 F6 · derivative.exercise_date: The option shares shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:06 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 4,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-009340 · doc4.xml · nonDerivative · entry 1 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,194 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs will vest fully on March 1, 2020, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · price: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs will vest fully on March 1, 2020, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 18:54 UTC | Forty Seven, Inc. FTSV · Entity 16035 | GrantStock Option (right to buy) · Derivative | 10,322 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001225208-19-009285 · doc4.xml · derivative · entry 1 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,322 Underlying: Common Stock · 10,322 shares Expires 2029-06-11 F1 · derivative.exercise_date: The shares subject to the option vest on the one-year anniversary of the grant date, subject to reporting person's continuous service on such date. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| August 23, 2018 Filed Aug 23, 2018 19:32 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | PurchaseCommon Stock | 50,355 | $26.65 | $1,341,809.69 |
DisclosureSEC source: 0001225208-18-012883 · doc4.xml · nonDerivative · entry 3 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust (Trustees) Disclosed balance after: 449,053 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.41 to $26.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust. Read SEC document |
| August 22, 2018 Filed Aug 23, 2018 19:32 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | PurchaseCommon Stock | 202,082 | $26.09 | $5,273,006.46 |
DisclosureSEC source: 0001225208-18-012883 · doc4.xml · nonDerivative · entry 2 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust (Trustees) Disclosed balance after: 398,698 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.89 to $26.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust. Read SEC document |
| August 21, 2018 Filed Aug 23, 2018 19:32 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | PurchaseCommon Stock | 137,563 | $25.17 | $3,462,570.76 |
DisclosureSEC source: 0001225208-18-012883 · doc4.xml · nonDerivative · entry 1 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust (Trustees) Disclosed balance after: 196,616 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionSeries A-1 Preferred Stock · Derivative | 667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 16 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F4 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionSeries B Preferred Stock · Derivative | 945,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 15 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (SHV) Disclosed balance after: 0 Underlying: Common Stock · 945,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionSeries A-2 Preferred Stock · Derivative | 774,165 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 14 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (SHV) Disclosed balance after: 0 Underlying: Common Stock · 774,165 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionSeries A-1 Preferred Stock · Derivative | 1,052,146 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 13 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (SHV) Disclosed balance after: 0 Underlying: Common Stock · 1,052,146 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionSeries B Preferred Stock · Derivative | 73,686 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 12 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (NEST) Disclosed balance after: 0 Underlying: Common Stock · 73,686 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionSeries A-2 Preferred Stock · Derivative | 73,159 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 11 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (NEST) Disclosed balance after: 0 Underlying: Common Stock · 73,159 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionSeries A-1 Preferred Stock · Derivative | 68,530 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · derivative · entry 10 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (NEST) Disclosed balance after: 0 Underlying: Common Stock · 68,530 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionCommon Stock | 667 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 9 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 4,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F4 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | PurchaseCommon Stock | 4,252 | $16.00 | $68,032.00 |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 8 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 4,252 F4 · ownership.nature: Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | PurchaseCommon Stock | 134,735 | $16.00 | $2,155,760.00 |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 7 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (SHV) Disclosed balance after: 2,906,372 F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionCommon Stock | 774,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 6 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (SHV) Disclosed balance after: 2,771,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionCommon Stock | 945,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 5 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (SHV) Disclosed balance after: 1,997,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionCommon Stock | 1,052,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 4 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (SHV) Disclosed balance after: 1,052,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F3 · ownership.nature: Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionCommon Stock | 68,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 3 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (NEST) Disclosed balance after: 215,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionCommon Stock | 73,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 2 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (NEST) Disclosed balance after: 146,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:42 UTC | Forty Seven, Inc. FTSV · Entity 16035 | ConversionCommon Stock | 73,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-011382 · doc4.xml · nonDerivative · entry 1 BIRD JEFFREY W · CIK 0001250409 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership (NEST) Disclosed balance after: 73,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The issuer's preferred stock automatically converted into issuer's common stock on a one-to-one basis immediately upon the closing of the issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:05 UTC | Venus Concept Inc. HAIR · Entity 55304 | GrantStock Option (Right to Buy) · Derivative | 13,708 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0000899243-18-016754 · doc4.xml · derivative · entry 1 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,708 Underlying: Common Stock · 13,708 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option will vest in full on the earlier of (A) June 13, 2019 or (B) immediately prior to the next annual meeting of the Company's stockholders, subject to continued service on the board of directors through each applicable vesting date. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 17:01 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $42.81 | $0.00 |
DisclosureSEC source: 0001225208-18-010489 · doc4.xml · derivative · entry 5 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-07 F6 · derivative.exercise_date: The option shares shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 17:01 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-010489 · doc4.xml · nonDerivative · entry 1 BIRD JEFFREY W · CIK 0001250409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs will vest fully on March 1, 2019, subject to the reporting person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. F2 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.